How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,794 results for

Ventilator-Associated Pneumonia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Antimicrobial prescribing: ceftolozane with tazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia

Antimicrobial prescribing: ceftolozane with tazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia Antimicrobial prescribing: ceftolozane with tazobactam for treating hospital-acquired pneumonia, including ventilator- associated pneumonia Evidence summary Published: 18 December 2019 www.nice.org.uk/guidance/es22 pathways K Ke ey messages y messages The content of this evidence review was up-to-date in December 2019. See summaries of product (...) /tazobactam for more information). In August 2019, the indication for ceftolozane with tazobactam was extended to include treating hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) in adults (Zerbaxa: Procedural steps taken and scientific information after authorisation). Evidence for using ceftolozane with tazobactam for treating HAP and VAP is from 1 phase 3 randomised controlled non-inferiority trial (ASPECT-NP). ASPECT-NP found that a high dose of ceftolozane

2020 National Institute for Health and Clinical Excellence - Advice

2. Ceftolozane/tazobactam (Zerbaxa) - hospital acquired pneumonia, including ventilator-associated pneumonia

Ceftolozane/tazobactam (Zerbaxa) - hospital acquired pneumonia, including ventilator-associated pneumonia Published 09 December 2019 1 Statement of advice SMC2256 ceftolozane / tazobactam 1g/0.5g powder for concentrate for solution for infusion (Zerbaxa®) Merck Sharp & Dohme Limited 8 November 2019 ADVICE: in the absence of a submission from the holder of the marketing authorisation ceftolozane / tazobactam (Zerbaxa®) is not recommended for use within NHSScotland. Indication under review (...) : In adults for the treatment of hospital acquired pneumonia, including ventilator-associated pneumonia. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines Consortium and was arrived at after careful consideration

2019 Scottish Medicines Consortium

6. PneuX for preventing ventilator-associated pneumonia in intensive care

PneuX for preventing ventilator-associated pneumonia in intensive care PneuX for pre PneuX for prev venting v enting ventilator-associated entilator-associated pneumonia in intensiv pneumonia in intensive care e care Medtech innovation briefing Published: 10 November 2015 nice.org.uk/guidance/mib45 pathways Summary Summary The PneuX tube system is intended for airway management in critically ill patients who are having mechanical ventilation. It is designed to prevent ventilator-associated (...) pneumonia by minimising the risk of pulmonary aspiration and micro-aspiration in patients having ventilation for 24 hours or more. One randomised controlled trial in high-risk cardiac patients found that the PneuX system was associated with a statistically significant reduction in the incidence of ventilator-associated pneumonia compared with a standard endotracheal tube. A PneuX endotracheal tube costs £150 and a PneuX tracheostomy tube costs £175 (both excluding VAT). © NICE 2018. All rights reserved

2015 National Institute for Health and Clinical Excellence - Advice

7. The TaperGuard Evac oral tracheal tube for mechanically ventilated intensive care patients at risk of ventilator-associated pneumonia

The TaperGuard Evac oral tracheal tube for mechanically ventilated intensive care patients at risk of ventilator-associated pneumonia Shile Shiley Endotr y Endotracheal T acheal T ube with T ube with T aperGuard Cuff aperGuard Cuff for intensiv for intensive care patients at risk of e care patients at risk of v ventilator-associated pneumonia entilator-associated pneumonia Medtech innovation briefing Published: 2 March 2015 nice.org.uk/guidance/mib22 pathways Summary Summary The T aperGuard (...) Evac oral tracheal tube is intended for airway management in critically ill patients needing mechanical ventilation. Two randomised controlled trials comparing the use of T aperGuard Evac with conventional tubes found no statistically significant differences between the groups in the incidence of ventilator-associated pneumonia, time to onset of ventilator-associated pneumonia, or length of intensive care unit stay. Using T aperGuard Evac costs £111.07 (for a box of 10 single-use tubes), plus

2015 National Institute for Health and Clinical Excellence - Advice

8. Is Zero Ventilator-Associated Pneumonia Achievable?: Practical Approaches to Ventilator-Associated Pneumonia Prevention. (Abstract)

Is Zero Ventilator-Associated Pneumonia Achievable?: Practical Approaches to Ventilator-Associated Pneumonia Prevention. Ventilator-associated pneumonia (VAP) remains a significant clinical entity with reported incidence rates of 7% to 15%. Given the considerable adverse consequences associated with this infection, VAP prevention became a core measure required in most US hospitals. Many institutions implemented effective VAP prevention bundles that combined head of bed elevation, hand hygiene

2018 Clinics in Chest Medicine

9. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Full Text available with Trip Pro

International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European The most recent European guidelines and task force reports on hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) were published almost 10 years ago. Since then, further randomised clinical trials of HAP and VAP have

2017 European Respiratory Journal

10. Semi-recumbent position versus supine position for the prevention of ventilator-associated pneumonia in adults requiring mechanical ventilation. Full Text available with Trip Pro

Semi-recumbent position versus supine position for the prevention of ventilator-associated pneumonia in adults requiring mechanical ventilation. Ventilator-associated pneumonia (VAP) is associated with increased mortality, prolonged length of hospital stay and increased healthcare costs in critically ill patients. Guidelines recommend a semi-recumbent position (30º to 45º) for preventing VAP among patients requiring mechanical ventilation. However, due to methodological limitations in existing (...) systematic reviews, uncertainty remains regarding the benefits and harms of the semi-recumbent position for preventing VAP.To assess the effectiveness and safety of semi-recumbent positioning versus supine positioning to prevent ventilator-associated pneumonia (VAP) in adults requiring mechanical ventilation.We searched CENTRAL (2015, Issue 10), which includes the Cochrane Acute Respiratory Infections Group's Specialised Register, MEDLINE (1946 to October 2015), EMBASE (2010 to October 2015), CINAHL

2016 Cochrane

11. Oral hygiene care for critically ill patients to prevent ventilator-associated pneumonia. Full Text available with Trip Pro

Oral hygiene care for critically ill patients to prevent ventilator-associated pneumonia. Ventilator-associated pneumonia (VAP) is defined as pneumonia developing in people who have received mechanical ventilation for at least 48 hours. VAP is a potentially serious complication in these patients who are already critically ill. Oral hygiene care (OHC), using either a mouthrinse, gel, toothbrush, or combination, together with aspiration of secretions, may reduce the risk of VAP (...) in these patients.To assess the effects of oral hygiene care on incidence of ventilator-associated pneumonia in critically ill patients receiving mechanical ventilation in hospital intensive care units (ICUs).We searched the following electronic databases: Cochrane Oral Health's Trials Register (to 17 December 2015), the Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library, 2015, Issue 11), MEDLINE Ovid (1946 to 17 December 2015), Embase Ovid (1980 to 17 December 2015), LILACS BIREME

2016 Cochrane

12. Silver-coated endotracheal tubes for prevention of ventilator-associated pneumonia in critically ill patients. Full Text available with Trip Pro

Silver-coated endotracheal tubes for prevention of ventilator-associated pneumonia in critically ill patients. Ventilator-associated pneumonia (VAP) is one of the most common nosocomial infections in intubated and mechanically ventilated patients. Endotracheal tubes (ETTs) appear to be an independent risk factor for VAP. Silver-coated ETTs slowly release silver cations. It is these silver ions that appear to have a strong antimicrobial effect. Because of this antimicrobial effect of silver

2015 Cochrane

13. Prevention of ventilator-associated pneumonia in newborns. (Abstract)

Prevention of ventilator-associated pneumonia in newborns. The aim of the study is to optimize the prevention of the development of ventilator-associated pneumonia in newborns by developing a method for tracheal rehabilitation and assessment of its effectiveness.Materials and methods: A prospective cohort randomized clinical study was organized, particularly artificial ventilation of the lungs was conducted on 90 newborns. Patients were divided into two groups. In the main group (n = 50 (...) tracheal sanation on the outer surface of the intubation tube in newborns units that undergo artificial ventilation of the lungs exhibit high efficiency against the main types of microorganisms that are dangerous from the point of view of the development of ventilator-associated pneumonia. The use of prophylactic tracheal sanitization in newborns - patients of neonatal intensive care units, which undergoes artificial ventilation of the lungs, can significantly lower the frequency of the implementation

2018 Wiadomosci lekarskie (Warsaw, Poland : 1960) Controlled trial quality: uncertain

14. The Effects of Gastrointestinal Function on the Incidence of Ventilator-associated Pneumonia in Critically Ill Patients. Full Text available with Trip Pro

The Effects of Gastrointestinal Function on the Incidence of Ventilator-associated Pneumonia in Critically Ill Patients. To investigate the effect of gastrointestinal function on the incidence of ventilator-associated pneumonia (VAP) in critically ill patients.From August 2012 to June 2016, 160 critically ill patients in the ICU (Intensive Care Unit) of our hospital were selected as the research group; patients were divided equally into an observation group and a control group, 80 patients

2018 Open medicine (Warsaw, Poland) Controlled trial quality: uncertain

15. Subglottic secretion drainage for the prevention of ventilator-associated pneumonia: A systematic review and meta-analysis

Subglottic secretion drainage for the prevention of ventilator-associated pneumonia: A systematic review and meta-analysis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2016 PedsCCM Evidence-Based Journal Club

16. The multistep road to ventilator-associated lung abscess: A retrospective study of S.aureus ventilator-associated pneumonia. Full Text available with Trip Pro

The multistep road to ventilator-associated lung abscess: A retrospective study of S.aureus ventilator-associated pneumonia. We observed some cases of lung abscess (LA) in ICU patients suffering S.aureus ventilator-associated pneumonia (S.aureus-VAP). We aimed to assess which of the host and/or bacteria-related features are associated with LA.We conducted a retrospective study from January 2009 to July 2013 in a trauma surgical ICU within a teaching hospital. All adult patients presenting

2017 PLoS ONE

17. Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia. Full Text available with Trip Pro

Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia. The US Food and Drug Administration solicited evidence-based recommendations to improve guidance for studies of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).We analyzed 7 HABP/VABP datasets to explore novel noninferiority study endpoints and designs, focusing on alternatives to all-cause mortality (ACM).ACM at day 28 differed (...) evaluation (APACHE) II score. Only patients in the nonventilated HABP group were able to report pneumonia symptom changes.If disease groups and patient characteristics in future studies produce an ACM rate so low (<10%-15%) that a fixed noninferiority margin of 10% cannot be justified (requiring an odds ratio analysis), an ACM+ endpoint could lower sample size. Enrichment of studies with patients with a higher severity of illness would increase ACM. Data on symptom resolution in nonventilated HABP

2019 Journal of Infectious Diseases

18. An Observational Veneto research on Ventilator Associated Pneumonia (OVeRVAP): attributable mortality and cumulative incidence of ventilator-associated pneumonia. (Abstract)

An Observational Veneto research on Ventilator Associated Pneumonia (OVeRVAP): attributable mortality and cumulative incidence of ventilator-associated pneumonia. The relationship between ventilator-associated pneumonia (VAP) and mortality varies from study to study, and its entity is uncertain due a considerable variation in the attributable mortality. The aim of this study was to evaluate the relationship between VAP frequency and mortality in a cohort of mechanically ventilated patients.A

2017 Minerva anestesiologica

19. Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia: Implications for Optimal Antimicrobial Therapy Ventilator-Associated Bacterial Pneumonia Study Group. Full Text available with Trip Pro

Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia: Implications for Optimal Antimicrobial Therapy Ventilator-Associated Bacterial Pneumonia Study Group. Ventilator-associated bacterial pneumonia (VABP) is a difficult therapeutic problem. Considerable controversy exists regarding the optimal chemotherapy for this entity. The recent guidelines of the Infectious Diseases Society of America

2017 Antimicrobial Agents and Chemotherapy

20. Probiotic prophylaxis to prevent ventilator associated pneumonia (VAP) in children on mechanical ventilation: an open-label randomized controlled trial

Probiotic prophylaxis to prevent ventilator associated pneumonia (VAP) in children on mechanical ventilation: an open-label randomized controlled trial PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2015 PedsCCM Evidence-Based Journal Club

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>